Peptide Reference
PE-22-28
PE-22-28
A synthetic peptide derived from Spadin that acts as a TREK-1 channel blocker. Investigated for rapid antidepressant effects similar to ketamine but without dissociative properties.
Status
research
Category
cognitive
Typical cost
$60-150/vial (10mg)
Mechanism
Blocks TREK-1 potassium channels, leading to increased neuronal excitability and enhanced neuroplasticity. Similar mechanism to ketamine's antidepressant effects but more targeted.
Potential benefits
- Rapid antidepressant effects
- Enhanced neuroplasticity
- Improved mood
- No dissociation
- Non-addictive
Reported side effects
- Unknown long-term effects
- Headache
- Nasal irritation
- Mild stimulation
Common dosing references
intranasal
10-100mcg · Daily
2-4 weeks
Research notes
PE-22-28 antidepressant effects in rodents
2016
Demonstrated rapid onset antidepressant effects in animal models within hours
Regulatory and sourcing notes
Preclinical research only. Not FDA-approved. No human trials completed.
Research chemical with limited availability. Very early stage compound.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides